CONNEQT Health has expanded its U.S. Phase 2b clinical trial contract from 30 to 45 investigational sites, after its wholly owned subsidiary, ATCOR Medical, Inc., executed a contract amendment on 9 November 2026. The amendment adds US$0.24 million and lifts total contract value to US$0.95 million, a 33% increase on the original contract.
The counterparty is a privately owned U.S.-based biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases (refer ASX announcement of 28 October 2025). The amendment reflects the addition of a second study visit to the trial protocol, and the extra revenue comes from an existing customer expanding scope under the same contract.
Craig Cooper, CEO, CONNEQT Health
“…It reflects the growing demand from pharmaceutical sponsors for our vascular assessment platforms and services.”
What the amendment delivers
Under the amendment, CONNEQT will supply the following additional scope:
- 15 additional SphygmoCor® XCEL systems
- 30 additional Oscar 2 ABPM systems
- Equipment leased for approximately seven months
- Equipment configuration, virtual operator training and certification, ongoing technical support, and data management services
The incremental value is inclusive of equipment leasing, operational support and data management services. The table below sets out the contract value before and after the amendment.
| Item | Sites | Contract value (US$) | Contract value (A$ approx.) |
|---|---|---|---|
| Original contract | 30 | US$0.72 million | n/a |
| Amendment increment | 15 | US$0.24 million | approximately A$0.34 million |
| Total | 45 | US$0.95 million | approximately A$1.36 million |
Why vascular endpoints matter in trials
A cardiovascular endpoint is a measured outcome of the heart or blood vessels that helps show whether a treatment works. Drug sponsors rely on dependable measurements to judge results.
Mr Cooper described SphygmoCor’s role as “generating reliable cardiovascular endpoints” in the trial.
When big ASX news breaks, our subscribers know first
Payment terms and revenue recognition
The commercial terms of the amendment are:
- A non-refundable initiation fee of 30% of the amendment value is payable on execution.
- Equipment lease and other ongoing charges are invoiced monthly over the extended lease period.
- Unit pricing and all other terms are unchanged from the original contract, including confidentiality and termination provisions customary in agreements of this type.
- Revenue will be recognised progressively over the duration of the trial.
Upfront cash on execution, followed by monthly invoicing, gives the amendment a staged cash profile. Mr Cooper tied the expansion to the “growing demand from pharmaceutical sponsors” for CONNEQT’s vascular assessment platforms and services.
Ready to Learn More About CONNEQT Health’s Expanding U.S. Phase 2b Trial?
CONNEQT Health has lifted its Phase 2b contract from 30 to 45 sites, adding US$0.24 million and taking total contract value to US$0.95 million. The expansion reflects growing pharmaceutical sponsor demand for its SphygmoCor® and Oscar 2 vascular assessment platforms.
Discover more about the company’s technology, projects and growth strategy by visiting the CONNEQT Health website. Explore how its cardiovascular assessment solutions are positioned to support future clinical trial opportunities.